BDTX 8-K 2026-11-10

Black Diamond Therapeutics, Inc. (BDTX) 8-K dated 2026-11-10 — accession 0001701541-26-000030.

Black Diamond Therapeutics, Inc. (BDTX) is a biotechnology company listed on NASDAQ.

BDTX: Black Diamond Therapeutics Announces Positive Updated Silevertinib Phas…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported BDTX revenue for 2025-12-31 was $70.0M. Net income was $22.4M. BDTX currently screens at market cap $95.7M.

Not investment advice. The BDTX SEC hub lists recent forms. The stock page is the research view.